| 000 | 01687 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516060100.0 | ||
| 264 | 0 | _c20111122 | |
| 008 | 201111s 0 0 eng d | ||
| 022 | _a1791-7530 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYokota, Tomoya | |
| 245 | 0 | 0 |
_aDocetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. _h[electronic resource] |
| 260 |
_bAnticancer research _cOct 2011 |
||
| 300 |
_a3535-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCisplatin _xadverse effects |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 |
_aEsophageal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPostoperative Complications _xetiology |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aTaxoids _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHatooka, Shunzo | |
| 700 | 1 | _aUra, Takashi | |
| 700 | 1 | _aAbe, Tetsuya | |
| 700 | 1 | _aTakahari, Daisuke | |
| 700 | 1 | _aShitara, Kohei | |
| 700 | 1 | _aNomura, Motoo | |
| 700 | 1 | _aKondo, Chihiro | |
| 700 | 1 | _aMizota, Ayako | |
| 700 | 1 | _aYatabe, Yasushi | |
| 700 | 1 | _aShinoda, Masayuki | |
| 700 | 1 | _aMuro, Kei | |
| 773 | 0 |
_tAnticancer research _gvol. 31 _gno. 10 _gp. 3535-41 |
|
| 999 |
_c21202145 _d21202145 |
||